E. Christine Thomas's most recent trade in Femasys Inc was a trade of 55,090 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 28, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Femasys Inc | Christine E. Thomas | Chief Reg & Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 55,090 | 55,090 | - | - | Stock Option (Right to Buy) | |
Femasys Inc | Christine E. Thomas | Chief Reg & Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 28,682 | 28,682 | - | - | Stock Option (Right to Buy) | |
Femasys Inc | Christine E. Thomas | Chief Reg & Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 23,600 | 23,600 | - | - | Stock Option (Right to Buy) | |
Femasys Inc | E. Christine Thomas | SVP, Regulatory & Clinical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 32,600 | 32,600 | - | - | Stock Option (Right to Buy) | |
Femasys Inc | Christine E. Thomas | SVP, Regulatory & Clinical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |